目的:复发性和转移性头颈部鳞状细胞癌(HNSCC)的预后较差。尽管免疫检查点抑制剂已经扩大了HNSCC的治疗选择,反应率很低。或者,正在开发癌症疫苗和T细胞疗法。需要鉴定有用的常见癌症抗原并确认人白细胞抗原(HLA)I类表达。
方法:对10种抗原进行了免疫组织化学分析(FOXM1,TGFBI,SPARC,HSP105α,WT1,AFP,GPC3,PP-RP,KIF20A,KM-HN-1)和HLAI类,使用56例手术病例的标本。染色强度,染色阳性区域的百分比,并评价染色在肿瘤细胞和正常组织中的定位。
结果:FOXM1,TGFBI,SPARC,HSP105α在肿瘤细胞中比在正常细胞中更占优势。这些抗原在肿瘤细胞中的表达率为60.7%,58.9%,73.2%,50.0%,分别。关于网站,这些抗原在口腔癌中的表达率高达57.1%,71.4%,81.0%,和66.7%,分别。此外,在所有病例中,HLAI类的表达为83.9%。其中,68.1%在质膜上表达。
结论:FOXM1,TGFBI,SPARC,HSP105α可能是有用的常见癌症抗原,在许多情况下,I类HLA在癌细胞的质膜上表达。结果表明,癌症疫苗和T细胞疗法可能是HNSCC治疗的临床可行选择。
OBJECTIVE: The prognosis of recurring and metastatic head and neck squamous cell carcinoma (HNSCC) is poor. Although immune checkpoint inhibitors have expanded the treatment options for HNSCC, the response rates are low. Alternatively, cancer vaccines and T-cell therapies are being developed. Identification of useful common cancer antigens and confirmation of human leukocyte antigen (HLA) class I expression are required.
METHODS: Immunohistochemistry analyses were performed for 10 antigens (FOXM1, TGFBI, SPARC, HSP105α, WT1, AFP, GPC3, PP-RP, KIF20A, KM-HN-1) and HLA class I using specimens of 56 surgical cases. Staining intensity, percentage of stain-positive areas, and localization of staining in the tumor cells and normal tissue were evaluated.
RESULTS: Staining of FOXM1, TGFBI, SPARC, and HSP105α was more predominant in tumor cells than that in normal cells. The expression rates of these antigens in tumor cells were 60.7%, 58.9%, 73.2%, and 50.0%, respectively. Regarding sites, the expression rates of these antigens in oral cancer were high at 57.1%, 71.4%, 81.0%, and 66.7%, respectively. Furthermore, the expression of HLA class I was 83.9% in all cases. Of these, 68.1% showed expression on the plasma membrane.
CONCLUSIONS: FOXM1, TGFBI, SPARC, and HSP105α could be useful common cancer antigens, and HLA class I is expressed on the plasma membrane of cancer cells in many cases. The results suggest that cancer vaccines and T-cell therapy may be clinically viable options for HNSCC treatment.